Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested ...
Fintel on MSN1d
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM)Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...
Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish ...
In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...
Donald Trump's commerce secretary nominee said Wednesday that he favors "across-the-board" tariffs and a country-based ...
‘Survivor’: Michele Fitzgerald Defends ‘Controversial’ Season 32 Win Against Critics (VIDEO)
For exclusive news and updates, subscribe to our Survivor Newsletter: It’s been nearly 10 years since Michele Fitzgerald was crowned the winner of Survivor Season 32, but she’s still haunted ...
In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $76.00. The company’s shares ...
On Wednesday, Cantor Fitzgerald analysts maintained an Overweight rating on Applied Blockchain Inc (NASDAQ: APLD) stock. The revision follows Applied Digital Corp.'s disclosure of its second ...
Cantor Fitzgerald raised the firm’s price target on TripAdvisor (TRIP) to $14 from $11 and keeps an Underweight rating on the shares as part of a broader note on Internet Stocks. The fundamental ...
Cantor Fitzgerald analyst Deepak Mathivanan downgraded Sabre (SABR) to Neutral from Overweight with a price target of $4, down from $5, after assuming coverage of the name. Cantor expects fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback